ArticleVeterinary research2025
TRIM7 suppresses transmissible gastroenteritis virus replication by targeting the degradation of N protein and activating RIG-I-mediated type I IFN antiviral response.
Article in Veterinary research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Transmissible gastroenteritis virus (TGEV) is a major enteric pathogen causing severe diarrhea in swine, with substantial implications for the biosecurity of intensive pig production worldwide. The E3 ubiquitin ligase TRIM7 has emerged as a key regulator of host antiviral immunity, yet its role in TGEV infection remains elusive. Here, we report that TRIM7 is abundantly expressed in porcine intestinal tissue and significantly upregulated upon TGEV challenge in IPEC-J2 cells. Functional studies demonstrated that TRIM7 restricts TGEV replication in IPEC-J2 cells through two distinct mechanisms. Firstly, molecular interaction and co-immunoprecipitation assays revealed that TRIM7 mediates ubiquitin-dependent degradation of the TGEV nucleocapsid (N) protein. Secondly, RNA-seq analysis combined with RIG-I signaling modulation experiments established that TRIM7 enhances RIG-I-mediated type I interferon (IFN) signaling to suppress viral propagation. These findings uncover a dual antiviral role for TRIM7 in countering TGEV infection, highlighting its potential as a therapeutic target for TGEV control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.